AST Stock, Asterias Biotherapeutics Inc. Common Series A Information

Asterias Biotherapeutics Inc is a biotechnology company engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The company has two core technology platforms. The first is an immunotherapy platform to teach cancer patients immune systems to attack their tumors. The second is pluripotent stem cell platform. From immunotherapy platform it is developing AST-VAC1, an autologous product candidate for the treatment of acute myelogenous leukemia; and AST-VAC2, an allogeneic, cancer vaccine candidate designed to stimulate patient immune responses; and through pluripotent it has developed AST-OPC1, which is for the treatment of spinal cord injury, multiple sclerosis, and stroke. All the activities of the firm are operated through United States.